Containing Chemically Combined Protein Or Biologically Active Polypeptide Patents (Class 525/54.1)
-
Publication number: 20120097613Abstract: The present invention relates to imprinted polymer nanoparticles. In particular, the present invention provides imprinted polymer nanopaticles polymerized in the presence of a target molecule (e.g., peptide), wherein the imprinted polymer nanoparticles comprise vinyl, acryl, and/or methacryl monomers, wherein the monomers have affinity for the target molecule. The present invention also relates to methods of using imprinted polymer nanoparticles in biomoacromolecular purification methods (e.g., to purify monoclonal antibodies or hormones), in toxin elimination methods (e.g., hemoperfusion), in diagnostics, in research, as well as in therapeutic methods (e.g., therapeutic methods where antisera or monoclonal antibodies are normally employed).Type: ApplicationFiled: January 11, 2010Publication date: April 26, 2012Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Yu Hoshino, Kenneth J. Shea
-
Publication number: 20120095166Abstract: Polymers having the formula R(LE)X wherein R is a polymeric core having a number average molecular weight of from 5000 to 7,000,000 daltons and x endgroups, E is an endgroup that is covalently linked to polymeric core R by linkage L, L is a divalent oligomeric chain having at least 5 identical repeat units that is capable of self-assembly with L chains on adjacent molecules of the polymer, and the moieties (LE)X in the polymer may be the same as or different from one another. Monomers, oligomers, or other reactive structures otherwise analogous to known Self Assembled Monolayers but with at least one reactive chemical group capable of binding them to the terminus of a polymer, so that the thiol-free SAM analogue becomes the self-assembling surface modifying endgroup of that polymer, may be designed. Use of the polymer to fabricate a configured article from the surface-modified polymer or to fabricate a coating or topical treatment on an article made from another material.Type: ApplicationFiled: October 14, 2011Publication date: April 19, 2012Inventors: Robert S. WARD, Keith R. McCREA, Yuan TIAN, James P. PARAKKA, Shanger WANG
-
Publication number: 20120093761Abstract: Nanoparticle-based vaccines, compositions, kits and methods are used for the effective delivery of one or more antigens in vivo for vaccination and antibody (e.g., monoclonal antibody) production, and for the effective delivery of peptides, proteins, siRNA, RNA or DNA to PAPCs or MHC class II positive cells (e.g. tumor cells). Antigens may be, for example, DNA that results in expression of the gene of interest and induction of a robust and specific immune response to the expressed protein in a subject (e.g., mammal). Antigens may also be immunogenic peptides or polypeptides that are processed and presented. In one embodiment, a nanoparticle -based method to deliver antigens in vivo as described herein includes injection of a vaccine composed of a DNA encoding at least one antigen, or at least one antigenic peptide or polypeptide conjugated to a charged dendrimer (e.g., PADRE-derivatized dendrimer) that is also conjugated to a T helper epitope (e.g., PADRE).Type: ApplicationFiled: April 1, 2010Publication date: April 19, 2012Applicant: UNIVERSITY OF MIAMIInventors: Pirouz M. Daftarian, Paolo Serafini, Vance Paul Lemmon, Angel Kaifer, Victor L. Perez, Wei Li, Bonnie Beth Blomberg
-
Publication number: 20120095165Abstract: The present application relates to an affinity material useful in antibody purification.Type: ApplicationFiled: April 9, 2010Publication date: April 19, 2012Applicant: BIOTAGE ABInventors: Anthony Rees, Börje Sellergren, Ecevit Yilmaz, Thomas Schrader
-
Publication number: 20120076749Abstract: The present invention relates, in general, to materials and methods for the preparation of modified blood factors which have low levels of water soluble polymer molecules conjugated to the blood factor but exhibit biological activity similar to or better than molecules having a higher number of water soluble polymer moieties.Type: ApplicationFiled: September 23, 2011Publication date: March 29, 2012Applicants: BAXTER HEALTHCARE S.A., BAXTER INTERNATIONAL INC.Inventors: Peter Turecek, Juergen Siekmann, Hanspeter Rottensteiner
-
Patent number: 8143347Abstract: The present invention relates to a proteinaceous construct comprising a blood coagulation factor, e.g., Factor VIII (FVIII), being bound to at least one water soluble polymer, including a poly(alkylene oxide) such as polyethylene glycol (PEG). Further the present invention relates to methods of preparing PEGylated blood coagulation factor, e.g., FVIII, in the presence of bound antibodies. The invention also relates to methods for prolonging the in vivo-half-life of blood coagulation factor, e.g., FVIII, in the blood of a mammal having a bleeding disorder associated with functional defects or deficiencies of blood coagulation factor, e.g., FVIII.Type: GrantFiled: October 14, 2009Date of Patent: March 27, 2012Assignees: Baxter International Inc., Baxter Healthcare S.A.Inventors: Artur Mitterer, Michael Graninger, Meinhard Hasslacher
-
Publication number: 20120070382Abstract: The present invention provides various fluorescent conjugated polymers with a BODIPY-based backbone. The invention also provides methods of using the polymers of the invention, such as for imaging and detection of cells, tumors, bacteria and viruses.Type: ApplicationFiled: December 23, 2009Publication date: March 22, 2012Applicant: MICHIGAN TECHNOLOGICAL UNIVERSITYInventor: Haiying Liu
-
Patent number: 8138265Abstract: A dihydroxyphenyl cross-linked macromolecular network is provided that is useful in artificial tissue and tissue engineering applications, particularly to provide a synthetic macromolecular network for a wide variety of tissue types. In particular, artificial or synthetic cartilage, vocal cord material, vitreous material, soft tissue material and mitral valve material are described. In an embodiment, the network is composed of tyramine-substituted and cross-linked hyaluronan molecules, wherein cross-linking is achieved via peroxidase-mediated dityramine-linkages that can be performed in vivo. The dityramine bonds provide a stable, coherent hyaluronan-based hydrogel with desired physical properties.Type: GrantFiled: January 29, 2009Date of Patent: March 20, 2012Assignee: The Cleveland Clinic FoundationInventors: Anthony Calabro, Aniq B. Darr, Richard A. Gross
-
Patent number: 8137688Abstract: A synthetic nucleus pulposus is provided that is useful in treatment of degenerative disc disease, augmentation of a degenerate disc, and alleviation of back pain. In an embodiment the synthetic nucleus pulposus comprises hyaluronan macromolecules that have been cross-linked via dihydroxyphenyl linkages. The synthetic nucleus pulposus restores or improves the water-retention capability of the disc. A method of treating an intervertebral disc with the cross-linked hyaluronan macromolecules is also provided. A method of regenerative therapy to address loss of cells of nucleus pulposus of an intervertebral disc based on treatment with the cross-linked hyaluronan macromolecules and mesenchymal stem cells is also provided.Type: GrantFiled: February 27, 2009Date of Patent: March 20, 2012Assignee: The Cleveland Clinic FoundationInventors: Peter A. Zahos, Anthony Calabro, Aniq B. Darr, Richard A. Gross
-
Publication number: 20120065330Abstract: The invention provides reagents and methods for conjugating a polymer specifically to the ?-amine of a polypeptide. The invention provides monofunctional, bifunctional, and multifunctional PEGs and related polymers having a terminal thioester moiety capable of specifically conjugating to the ?-amine of a polypeptide having a cysteine or histidine residue at the N-terminus. The invention provides reactive thioester-terminated PEG polymers that have suitable reactivity with an N-terminal cysteine or histidine residue of a polypeptide to produce an amide bond between the PEG molecule and the polypeptide.Type: ApplicationFiled: October 26, 2011Publication date: March 15, 2012Applicant: Nektar TherapeuticsInventors: Michael J. Roberts, Zhihao Fang
-
Publication number: 20120063954Abstract: The invention relates to a device and a method for depletion of hepcidin from blood for treatment of iron deficiency, in particular in anemic patients suffering from chronic renal failure, with the goal of increasing the availability of iron in the body and thus improving the treatment of the anemia. The hepcidin adsorbent comprises a matrix and a hepcidin-binding ligand covalently bonded to the matrix with an affinity having a dissociation constant KD of less than 200 nM.Type: ApplicationFiled: July 15, 2010Publication date: March 15, 2012Inventors: Jutta Passlick-Deetjen, Wolfgang Hofmann
-
Publication number: 20120064097Abstract: We provide monoclonal antibodies against interleukin-1? and tumor necrosis factor-? that remain biologically active in vitro when conjugated to high molecular weight polysaccharides. We report enhanced binding of these cytokines when their monoclonal antibodies are conjugated to alginate compared to non-conjugated monoclonal antibodies. In cell assays, polysaccharide-antibody constructs of the invention inhibited cytokine signaling to comparable levels as that of unmodified antibodies. Conjugation of cytokine-neutralizing antibodies to high molecular weight polymers enhances the affinities cytokine-binding moieties used as anti-inflammatory therapeutics.Type: ApplicationFiled: July 20, 2011Publication date: March 15, 2012Inventors: Newell R. Washburn, Liang Tso Sun
-
Publication number: 20120058536Abstract: The present invention relates to a polymer made of a primary amine functionalized polymer and a hemicellulose e.g. chitosan and xyloglucan, wherein the primary amine functionalized polymer is covalently bound to the hemicellulose, and to a cross-linking agent composition comprising the polymer. A method wherein manufacturing a cellulose containing product comprises the steps of; providing a cellulose containing product; treating said cellulose product with a cellulose adsorbing agent comprising a polymer made of a primary amine functionalized polymer and a hemicellulose e.g. chitosan and xyloglucan, and optionally other additives is also provided.Type: ApplicationFiled: May 27, 2010Publication date: March 8, 2012Applicant: SweTree Technologies ABInventors: Marcus Ruda, Rikard Slättegård
-
Publication number: 20120058556Abstract: A cell culture microcarrier includes (1) a polystyrene microcarrier base having a remnant of a carboxylic acid group, and (ii) a polypeptide conjugated to the base via the remnant of the carboxylic acid group. The polypeptide may contain a cell adhesive sequence, such as RGD. Cells cultured with such microcarriers exhibit peptide-specific binding to the microcarriers.Type: ApplicationFiled: July 28, 2010Publication date: March 8, 2012Inventors: Michelle Dawn Fabian, Timothy Edward Myers, Kyle Patrick Snyder, Florence Verrier
-
Publication number: 20120058153Abstract: This invention relates to compositions and methods that can be used immunize a subject against influenza. Generally, the compositions and methods include polypeptides obtained or derived from human influenza A virus hemagglutinin.Type: ApplicationFiled: August 19, 2011Publication date: March 8, 2012Applicant: Selecta Biosciences, Inc.Inventors: Petr Ilyinskii, Yun Gao, Grayson B. Lipford
-
Publication number: 20120058154Abstract: This invention relates to compositions and methods that can be used immunize a subject against influenza. Generally, the compositions and methods include peptides obtained or derived from human influenza A virus M2 protein.Type: ApplicationFiled: August 19, 2011Publication date: March 8, 2012Applicant: Selecta Biosciences, Inc.Inventors: Petr Ilyinskii, Yun Gao, Grayson B. Lipford
-
Publication number: 20120052097Abstract: Described herein are conjugates (e.g., therapeutic peptide-polymer conjugates and protein-polymer conjugates) and particles, which can be used, for example, in the treatment of a disorder such as cancer. Also described herein are mixtures, compositions and dosage forms containing the particles, methods of using the particles (e.g., to treat a disorder), kits including the conjugates (e.g., therapeutic peptide-polymer conjugates and protein-polymer conjugates) and particles, methods of making the conjugates (e.g., therapeutic peptide-polymer conjugates and protein-polymer conjugates) and particles, methods of storing the particles and methods of analyzing the particles.Type: ApplicationFiled: August 18, 2011Publication date: March 1, 2012Applicant: Cerulean Pharma Inc.Inventors: Oliver S. Fetzer, Jungyeon Hwang, Patrick Lim Soo, Pei-Sze Ng, Sonke Svenson
-
Publication number: 20120052579Abstract: A cell culture article including a microcarrier having a peptide-modified polymer surface of the formula (I) where AAj represents at least one covalently bonded peptide, j is an integer of from 5 to 50, m, n, o, Sur, X, R, R?, and the mer ratio (m-o:n:o), including salts thereof, are as defined herein. Also disclosed are methods for making and using the cell culture article, as defined herein.Type: ApplicationFiled: July 28, 2011Publication date: March 1, 2012Inventors: Simon Kelly Shannon, Florence Verrier
-
Publication number: 20120046184Abstract: Provided herein is a method for the isolation or removal of a cellular component from a cell that comprises the steps of applying a pulse of nanoparticles to the cell, allowing the nanoparticles to traffic through the cell for a period of time sufficient to allow the nanoparticles locate to and interact with the cellular component to be isolated, and separation of the nanoparticles and isolated cellular component from the cell.Type: ApplicationFiled: February 26, 2010Publication date: February 23, 2012Applicant: UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLINInventors: Kenneth Dawson, Iseult Lynch, Martin Lundqvist, Tommy Cedervall
-
Patent number: 8119392Abstract: This invention relates to biomaterials, biocompatible photoresists, and electroactive photoresists, and methods to engineer the interactions between biomaterials and cells. In one aspect, this invention provides for modifying surface topography through micro-patterning techniques that require no organic solvent development to reveal the lithographic patterns. Cells can be cultured on these surfaces directly and exhibit strong cell alignment features.Type: GrantFiled: April 30, 2004Date of Patent: February 21, 2012Assignee: The University of North Carolina at CharlotteInventors: Kenneth E. Gonsalves, Wei He
-
Publication number: 20120040581Abstract: The invention relates to a method for producing two- and three-dimensionally structured, microporous and nanoporous webs made up of nanofibers in any form with a very high covering or depositing degree of the fibers by means of a predefined conductive mold (template) as a collector and to the use of the webs according to the invention. The three-dimensional structure formation can be influenced in a directed manner by the deposition density of the nanofibers generated by means of an electrospinning process, which deposition density is adjustable through the accumulation time of the fibers.Type: ApplicationFiled: March 31, 2010Publication date: February 16, 2012Applicant: CENTRO DE ESTUDIOS INVESTIGACIONES TECNICAS DE GIPUZKOAInventor: Gyeong-Man Kim
-
Publication number: 20120035320Abstract: The present invention provides nucleic acid delivery polyplex complexes and anionic open polyplexes comprising a nucleic acid molecule reversibly bound to one or more of nucleic acid delivery polyplex complexes.Type: ApplicationFiled: April 4, 2011Publication date: February 9, 2012Applicant: University of Iowa Research FoundationInventors: Kevin G. Rice, Nicholas J. Baumhover, Christian A. Fernandez, Kevin Anderson, Mark D. Ericson, Jason T. Duskey, Koby Kizzire, Sanjib Khargharia, Samuel T. Crowley
-
Publication number: 20120034709Abstract: A surface modified substrate is produced by a method including reacting a substrate having a reactive functional group on a surface thereof with a functional group being reactive to the reactive functional group, and reacting the substrate with a compound represented by the general formula, wherein R1, R2 and R3 are each independently an alkyl group with a carbon number of 1 or more and 6 or less, m is an integer from 2 to 6, and n is 1 or 2.Type: ApplicationFiled: March 1, 2010Publication date: February 9, 2012Applicant: Shiseido Company, Ltd.Inventor: Katsuyuki Maeno
-
Publication number: 20120035321Abstract: The present disclosure relates to compounds and medical devices activated with a solvophobic material functionalized with a first reactive member and methods of making such compounds and devices.Type: ApplicationFiled: February 22, 2010Publication date: February 9, 2012Inventors: Sébastien Ladet, Philippe Gravagna
-
Publication number: 20120029150Abstract: The present disclosure relates to a method of forming fibers. First and second precursors, each possessing a core and at least one functional group known to have click reactivity, are mixed. The mixed precursors are then extruded under heat to cross-link during fiber production.Type: ApplicationFiled: February 22, 2010Publication date: February 2, 2012Inventors: Ahmad Robert Hadba, Sébastien Ladet
-
Patent number: 8106098Abstract: The present invention broadly relates to the field of protein modification, and, more specifically, to conjugates of proteins or analogs thereof to a water-soluble biocompatible polymer and methods of making and using the same.Type: GrantFiled: January 9, 2007Date of Patent: January 31, 2012Assignee: The General Hospital CorporationInventor: Mikhail I. Papisov
-
Patent number: 8105391Abstract: Provided herein are a method, which comprises implanting in a patient an implantable device comprising a coating that includes a PEGylated hyaluronic acid and a PEGylated non-hyaluronic acid biocompatible polymer and the methods of use thereof.Type: GrantFiled: April 1, 2010Date of Patent: January 31, 2012Assignee: Advanced Cardiovascular Systems, Inc.Inventors: Lothar W. Kleiner, Connie S. Kwok
-
Publication number: 20120020911Abstract: The present invention relates to biodegradable scaffolds composed of a naturally-occurring protein backbone cross-linked by a synthetic polymer. Specifically, the present invention provides PEGylated-fibrinogen scaffold and methods of generating and using same for treating disorders requiring tissue regeneration.Type: ApplicationFiled: July 13, 2011Publication date: January 26, 2012Applicant: Regentis Biomaterials Ltd.Inventors: Dror Seliktar, Liora Almany
-
Publication number: 20120014905Abstract: Novel compounds of the general formula (I): in which X represents a polymer; Q represents a linking group; W represents an electron-withdrawing moiety or a moiety preparable by reduction of an electron-withdrawing moiety; each of R1 and R2 independently represents a hydrogen atom or a C1-4alkyl group; and either Z1 represents a protein or a peptide linked to CR2 via a nucleophilic moiety, and Z2 represents a molecule linked to CR2 via a nucleophilic moiety, or Z1 and Z2 together represent a single group derived from a protein or peptide linked to CR via two nucleophilic moieties.Type: ApplicationFiled: March 4, 2010Publication date: January 19, 2012Inventors: Antony Robert Godwin, Stephen James Brocchini
-
Publication number: 20120016082Abstract: An initiator for the terminal group of the polymer product of an atom or group radical transfer polymerisation has an activated carboxyl or an amine group which is reacted with an amine or carboxyl (respectively) group containing biologically active compound. The initiator is preferably 4-(3-(2-bromo, 2-methyl-propionate)phenyl)-propionic acid N-hydroxysuccinimide ester or 2-bromo, 2-methyl-propionic acid N-hydroxysuccinimide ester. The monomers preferably comprise a zwitterionic monomer such as 2-methacryloxyethyl-2?-trimethyl ammoniumethyl phosphate inner salt.Type: ApplicationFiled: September 23, 2011Publication date: January 19, 2012Applicant: BIOCOMPATIBLES UK LIMITEDInventors: Andrew Lennard LEWIS, Simon William LEPPARD
-
Publication number: 20120014908Abstract: The present disclosure provides inter alia conjugates of formula (I): wherein n, R1, R2, Rx, Z, X, Y and Z are as defined herein. A conjugate of formula (I) can also be converted to a conjugate of formulae (II) or (III) as described herein. Without limitation, the conjugates can be used to make controlled release materials and chemical sensors.Type: ApplicationFiled: January 27, 2010Publication date: January 19, 2012Inventors: Todd C. Zion, Thomas M. Lancaster
-
Publication number: 20120015344Abstract: The disclosure generally relates to a particulate composition formed from a conductive polymer bound to magnetic nanoparticles. The particulate composition can be formed into a biologically enhanced, electrically active magnetic (BEAM) nanoparticle composition by further including a binding pair member (e.g., an antibody or a fragment thereof that specifically recognizes a virus strain or a virus surface protein) bound to the conductive polymer of the particulate composition. The disclosure further provides compositions, kits, detection apparatus, and methods for detecting specific viral strains including those with pandemic potential. In the various embodiments, a triplex including the BEAM nanoparticle, a virus or virally derived material (e.g. strain- and/or strain subtype specific viral surface protein or fragments thereof), and a viral strain subtype-specific binding pair member (e.g., a glycan that recognizes a specific virus strain subtype) is formed and detected, such as by use of a biosensor.Type: ApplicationFiled: May 11, 2011Publication date: January 19, 2012Applicant: 1. Board of Trustees of MICHIGAN STATE UNIVERSITYInventors: Evangelyn C. Alocilia, Tracy L. Kamikawa, Dorothy Elizabeth Scott, Michael C. Kennedy, Pei Zhang, Malgorzata Mikolajczyk, Lilin Zhong
-
Publication number: 20120009205Abstract: Disclosed is a process for preparing a pharmacologically active compound, in which at least one internal conjugation site of an Fc domain sequence is selected that is amenable to conjugation of an additional functional moiety by a defined conjugation chemistry through the side chain of an amino acid residue at the conjugation site. An appropriate amino acid residue for conjugation may be present in a native Fc domain at the conjugation site or may be added by insertion (i.e., between amino acids in the native Fc domain) or by replacement (i.e., removing amino acids and substituting different amino acids). In the latter case, the number of amino acids added need not correspond to the number of amino acids removed from the previously existing Fc domain. This technology may be used to produce useful compositions of matter and pharmaceutical compositions containing them.Type: ApplicationFiled: June 28, 2011Publication date: January 12, 2012Inventors: Colin V. GEGG, Kenneth W. Walker, Leslie P. Miranda, Fei Xiong
-
Publication number: 20120004183Abstract: This invention provides compositions and methods for producing translational components that expand the number of genetically encoded amino acids in eukaryotic cells. The components include orthogonal tRNAs, orthogonal aminoacyl-tRNA synthetases, pairs of tRNAs/synthetases and unnatural amino acids. Proteins and methods of producing proteins with unnatural amino acids in eukaryotic cells are also provided.Type: ApplicationFiled: June 23, 2011Publication date: January 5, 2012Applicant: The Scripps Research InstituteInventors: Alexander Deiters, T. Ashton Cropp, Jason W. Chin, J. Christopher Anderson, Peter G. Schultz
-
Patent number: 8088340Abstract: A biochip substrate capable of realizing the high detection accuracy by restricting a nonspecific adsorption or bonding of a substance to be detected, when used for a detection or analysis of protein, nucleic acids and the like. The biochip substrate is for fixing a biologically active substance on a surface of a solid substrate, and characterized in that it has a layer comprising a polymer compound obtained by copolymerizing an ethylenically unsaturated polymerizable monomer having an alkylene glycol residue, an ethylenically unsaturated polymerizable monomer having a functional group for fixing a biologically active substance and an ethylenically unsaturated polymerizable monomer having a cross-linkable functional group, on the surface of the substrate.Type: GrantFiled: March 14, 2006Date of Patent: January 3, 2012Assignees: Sumitomo Bakelite Company, Ltd., Somalogic, Inc.Inventors: Mitsutaka Matsumoto, Sumio Shibahara, Takayuki Matsumoto, Kanehisa Yokoyama, Sohei Funaoka, Daisuke Masuda, Michael Patrick Coleman, Dominic Zichi
-
Publication number: 20110318297Abstract: A protein nanocapsule having a single-protein core and a thin polymer shell anchored covalently to the protein core.Type: ApplicationFiled: March 9, 2010Publication date: December 29, 2011Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Yunfeng Lu, Ming Yan, Juanjuan Du
-
Patent number: 8080260Abstract: A composition comprising a human- or animal-derived extracellular matrix and a macromolecular network which is prepared ex vivo is provided that is useful in the repair of a tissue injury, particularly in repair of tears or gaps between a tendon and a bone, such as in a rotator cuff tear. In an embodiment, the composition comprises a human- or animal-derived extracellular matrix having impregnated therein a macromolecular network of hyaluronan macromolecules that have been cross-linked via dihydroxyphenyl linkages, so that the cross-linked network is interlocked within the extracellular matrix. The resulting HA-incorporated extracellular matrix can be supplied in the form of a patch to reinforce a tissue repair or cover a tissue defect.Type: GrantFiled: February 13, 2009Date of Patent: December 20, 2011Assignee: The Cleveland Clinic FoundationInventors: Kathleen Anne Derwin, Joseph Patrick Iannotti, LiKang Chin, Anthony Calabro
-
Publication number: 20110306657Abstract: The invention provides poly(alkyleneimine)-graft-biodegradable polymers and methods for preparing such polymers. The poly(alkyleneimine)-graft-chitosan polymers may optionally contain a targeting element. The poly(alkyleneimine)-graft polymers may be used to deliver a bioactive agent into a cell.Type: ApplicationFiled: August 25, 2011Publication date: December 15, 2011Inventors: Ye LIU, Kok Hou WONG, Guobin SUN, Chaobin HE, Kam W. LEONG
-
Patent number: 8076412Abstract: The present invention is directed to alkanal derivatives of water-soluble polymers such as poly(ethylene glycol), their corresponding hydrates and acetals, and to methods for preparing and using such polymer alkanals. The polymer alkanals of the invention are prepared in high purity and exhibit storage stability.Type: GrantFiled: October 20, 2010Date of Patent: December 13, 2011Assignee: Nektar TherapeuticsInventor: Antoni Kozlowski
-
Patent number: 8076463Abstract: The present invention relates to a proteinaceous construct (also designated as polymer-VWF-conjugate) comprising plasmatic and/or recombinant von Willebrand factor (VWF), said VWF being bound to at least one physiologically acceptable polymer molecule, as well as to a complex between said proteinaceous construct and at least one factor VIII (FVIII) protein. The physiologically acceptable polymer molecule can be, for instance, polyethylene glycol (PEG) or polysialic acid (PSA). Further the present invention relates to methods for prolonging the in vivo-half-life of VWF or FVIII in the blood of a mammal having a bleeding disorder associated with functional defects of or deficiencies of at least one of FVIII or VWF.Type: GrantFiled: January 14, 2011Date of Patent: December 13, 2011Assignees: Baxter International, Inc., Baxter Healthcare S.A.Inventors: Friedrich Scheiflinger, Peter Turecek, Juergen Siekmann
-
Patent number: 8071678Abstract: The invention provides reagents and methods for conjugating a polymer specifically to the ?-amine of a polypeptide. The invention provides monofunctional, bifunctional, and multifunctional PEGs and related polymers having a terminal thioester moiety capable of specifically conjugating to the ?-amine of a polypeptide having a cysteine or histidine residue at the N-terminus. The invention provides reactive thioester-terminated PEG polymers that have suitable reactivity with an N-terminal cysteine or histidine residue of a polypeptide to produce an amide bond between the PEG molecule and the polypeptide.Type: GrantFiled: October 11, 2010Date of Patent: December 6, 2011Assignee: Nektar TherapeuticsInventors: Michael J. Roberts, Zhihao Fang
-
Publication number: 20110294952Abstract: The invention generally relates to optimized drug conjugates.Type: ApplicationFiled: May 25, 2011Publication date: December 1, 2011Applicant: SynDevRXInventor: John S. Petersen
-
Publication number: 20110293522Abstract: Polymer surface modification method comprising the steps of first forming a surface of primary reactive end groups tethered to the polymer chain ends during fabrication of an article, and then modifying the reactive surface with bio-active molecules, hydrophilic and hydrophobic monomers, oligomers, or polymers to attain specific surface properties. Alternatively, a multifunctional coupling agent can be used to couple the primary reactive group to a second reactive group capable of reacting with a functional group associated with bio-active molecules, hydrophilic and hydrophobic monomers, oligomers, and polymers to attain specific surface properties. The invention involves bringing reactive endgroups to the surface with surface active spacer attached to the polymer chain end. The surface active spacer allows the migration and enrichment of reactive end groups to the surface during fabrication.Type: ApplicationFiled: November 16, 2009Publication date: December 1, 2011Applicant: DSM IP ASSETS B.V.Inventors: Shanger Wang, Robert S. Ward, Yuan Tian, Xuwei Jiang, Keith Mccrea, Scott Curtin
-
Publication number: 20110293554Abstract: This invention relates to a recombinant human G-CSF (rhG-CSF) dimer and its use in the treatment of neurological disorder. In particular, upon ischemic neural injury in animal, this invention can be used to protect neurons with the use of rhG-CSF dimer such that function of injured nerves can be restored. Serum half-life of G-CSF dimer of this invention is prolonged and the biological activity thereof is increased.Type: ApplicationFiled: May 23, 2011Publication date: December 1, 2011Applicant: GENERON (SHANGHAI) CORPORATION LTD.Inventors: Xiaoqiang YAN, Zhihua HUANG, Hongzhou YANG, Bill N.C. SUN, Yuliang HUANG
-
Publication number: 20110294161Abstract: Modified growth hormone polypeptide and uses thereof are provided.Type: ApplicationFiled: February 25, 2011Publication date: December 1, 2011Applicant: AMBRX, INC.Inventors: Ho Sung CHO, Thomas O. DANIEL, Richard D. DIMARCHI, Anna-Maria HAYS, Troy E. WILSON, Bee-Cheng SIM, David C. LITZINGER
-
Publication number: 20110293515Abstract: Heterofunctional segment-poly(ethylene glycol) polymers, conjugates of these molecules with therapeutic and/or imaging agents, and methods for their use are disclosed. The heterofunctional segment-poly(ethylene glycol) polymers are useful as drug delivery conjugates, i.e., the heterofunctional segment-poly(ethylene glycol) polymers can be covalently attached to therapeutic agents (e.g., pharmaceutically active agents) and serve as delivery vehicles for the therapeutic agents. The heterofunctional segment-poly(ethylene glycol) polymers are also useful as imaging agent conjugates, i.e. the heterofunctional segment-poly(ethylene glycol) polymers can be covalently attached to imaging agents (e.g., tracers, imaging atoms, and imaging molecules) and serve as delivery vehicles for the imaging agents. Also disclosed are methods for treating a subject by administering to the subject an effective amount of the polymers conjugated to a therapeutic agent, an imaging agent, or a mixture thereof.Type: ApplicationFiled: January 12, 2010Publication date: December 1, 2011Applicant: THE UAB RESEARCH FOUNDATIONInventors: Ahmad Safavy, James A. Bonner, Donald J. Buchsbaum
-
Publication number: 20110286923Abstract: Conjugates of a polymer having attached thereto an angiogenesis targeting moiety and a therapeutically active agent such as an anti-cancer agent or anti-angiogenesis agent, and processes of preparing same are disclosed. Pharmaceutical compositions containing these conjugates and uses thereof in the treatment of angiogenesis-related medical conditions such as cancer and cancer metastases are also disclosed.Type: ApplicationFiled: May 21, 2009Publication date: November 24, 2011Applicant: Fundacion de la Communidad Valenciana Centro de Investigacion principe felipeInventors: Ronit Satchi-Fainaro, Maria Jesus Vincent Docon
-
Publication number: 20110286958Abstract: Polymeric platinum amidomalonate complexes, where the platinum is in +2 or +4 oxidation state, and where the complexes optionally contain tumor seeking groups, are useful in the treatment of cancer.Type: ApplicationFiled: May 16, 2011Publication date: November 24, 2011Inventors: Paul Sood, N. Rao Ummaneni, Bruce Thurmond, Ryszard Zarzycki
-
Publication number: 20110286956Abstract: A novel multi-arm polyethylene glycol (PEG) (I) and preparation method thereof. Active derivatives (II) based on the multi-arm PEG. Gels formed of the active derivatives. Drug conjugates formed of the active derivatives and drug molecules and uses thereof in medical preparation. The multi-arm PEG is formed by polymerizing ethylene oxide with pentaerythritol oligomers as initiator, wherein PEG is the same or different and is a —(CH2CH2O)m-, the average value of m is an integer of 3-1000, l is an integer more than or equal to 2. An 8-arm PEG is preferred, wherein l is equal to 3. The active derivatives (II) comprise link groups X attached to PEG and active end groups F attached to X.Type: ApplicationFiled: September 28, 2009Publication date: November 24, 2011Applicant: BEIJING JENKEM TECHNOLOGY CO. LTD.Inventors: Xuan Zhao, Yuhe Zhao
-
Publication number: 20110288234Abstract: A nanoparticle including a polysiloxane base having an exterior surface and having a photosensitizer at least partly exposed at its exterior surface, said photosensitizer being secured to the exterior surface by loading the photosensitizer onto the surface after formation of the polysiloxane base of the nanoparticle. The nanoparticle may have tumor targeting moieties and may be post loaded with cyanine dye. The nanoparticle preferably includes post loaded moieties providing at least two of tumor specificity, photodynamic properties and imaging capabilities and the photosensitizer is tagged with a radioisotope. A method for preparation of the nanoparticle is also provided.Type: ApplicationFiled: February 19, 2009Publication date: November 24, 2011Applicants: The Research Foundation on State University of NY, Health Research, Inc.Inventors: Ravindra K. Pandey, Lalit N. Goswami, Allan Oseroff, Stephanie Pincus, Janet Morgan, Paras N. Prasad, Earl J. Bergey